Two-fraction HDR Monotherapy for Localized Prostate Cancer
Part of paid clinical trials in San Francisco, California.
- Sponsor
- University of California, San Francisco
- Study ID
- NCT05665738
- Status
- Recruiting
Conditions
- Localized Prostate Carcinoma
- Prostate Adenocarcinoma
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- High Dose Rate Monotherapy — RADIATIONHigh dose rate brachytherapy delivered in 13.5 Gy x 2 fractions over a single implant procedure 3 hours apart
Study Details
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart. HDR monotherapy has been established as safe and effective in this context, however previous studies have delivered 2 fractions on separate days, or at least 6 hours apart. Clinically, this regimen, if shown to be safe and effective in future studies, has the potential to reduce operative resources and logistical stresses on brachytherapy departments.
Key Dates
- Start date
- Sep 11, 2024
- Status verified
- Jun 2026
- Primary completion
- Feb 28, 2029
- Completion
- Feb 28, 2029
Study Design
- Enrollment
- 17 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: HDR brachytherapyParticipants will receive the same radiotherapy technique, methods, and delivery will as standard of care 3 hours apart instead of receiving the radiotherapy on separate days.
Primary Outcome Measure
Proportion of participants with treatment-related adverse events [ Time Frame: Up to 6 months ]
Central Contacts
- Imani Dunn877-827-3222
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94143 | 877-827-3222 I-Chow Hsu, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in San Francisco, CA
By research site
Related Studies
- Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate CancerEARLY_PHASE1 · Recruiting · Ivan de Kouchkovsky, MD · San Francisco, California
- Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical ProstatectomyPHASE2 · Recruiting · David Oh · San Francisco, California
- Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active SurveillancePHASE2 · Recruiting · University of California, San Francisco · San Francisco, California
- Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE TrialPHASE3 · Recruiting · NRG Oncology · Phoenix, Arizona